This document has been approved by HSA as of 04-10-2024
M-SG-00001862
Patient Card Version 3.0.1

Contact Information

Prescribing doctor's phone number:

Patient's name:

Prescribing doctor's name:

Date of Columvi® initiation:

[Optional] Date(s) of subsequent Columvi® infusion:

Roche

Important Safety Information for Patients receiving Columvi® *(glofitamab)*
Patient Card

- Please carry this card with you at all times while you are receiving **Columvi® (glofitamab)**
- Show this card to any doctor involved in your care.

Information for the Patient

Contact your doctor or get emergency help **right away** if you have **any** of these symptoms:

- Fever (100.4°F/38°C or higher)
- Fast heartbeat
- Chills
- Feeling dizzy or lightheaded
- Confusion
- Sleepiness
- Change in consciousness level
- Shortness of breath

Experiencing any of these symptoms could be due to **cytokine release syndrome or neurologic toxicity**, which requires immediate evaluation by a doctor.

These are not all the possible side effects of Columvi®. Tell your doctor if you have any symptom that bothers you or does not go away.

Cytokine Release Syndrome

- is a group of symptoms caused by small proteins called cytokines, released in your body during inflammation.
- may be caused by receiving **Columvi® (glofitamab)**

Information for the Treating Doctor

This patient has received **Columvi® (glofitamab) - which may cause cytokine release syndrome (CRS) or neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS).**

- Evaluate the patient immediately and treat symptoms.
- If CRS or neurologic toxicity (including ICANS) is suspected, please refer to section 2.2 of the **Columvi® (glofitamab)** Singapore Package Insert for further information on their management.
- **Contact the prescribing doctor** when possible – they may need to modify the next infusion of **Columvi® (glofitamab).**
- For more information about **Columvi® (glofitamab)**, please refer to the Singapore Package Insert.
- Company contact point - Roche Drug Safety Unit at singapore.drugsafety@roche.com